(Arg)9
(Synonyms: 九聚精氨酸,Nona-L-arginine; Peptide R9) 目录号 : GC34976
A cationic cell-penetrating peptide
Cas No.:143413-47-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | (Arg)9 is prepared as 100× stocks (500 μM) in normal saline and assessed in a concentration range from 0.1 to 15 μM. (Arg)9 is added to culture 96-well plate 15 min prior to glutamic acid or kainic acid exposure. Neuronal viability is quantitatively using the MTS assay[1]. |
Animal experiment: | Rats: (Arg)9 (D-isoform) is prepared in 100× stocks (500 μM in water and assessed in a concentration range from 0.1 to 20 μM. Rats are fasted overnight and subjected to filament permanent middle cerebral artery occlusion (MCAO). Thirty minutes post-MCAO rats are intravenously treated with (Arg)9 (1 μmol/kg in 600 μL over 5 minutes) or vehicle (normal saline for injection; 600 μL over 5 minutes). Treatments are randomized and all procedures are performed masked to treatment. Twenty-four hours post-MCAO infarct area assessment is performed[2]. |
References: [1]. Meloni BP, et al. The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures. Cell Mol Neurobiol. 2014 Mar;34(2):173-81. | |
(Arg)9 is a cationic cell-penetrating peptide.1,2 It has been used to deliver various cargo to cells, including fluorescent proteins and plasmids. (Arg)9 (5 and 10 ?M) also protects primary rat cortical neurons from glutamate-induced excitotoxicity.3
1.Chang, M., Chou, J.-C., and Lee, H.-J.Cellular internalization of fluorescent proteins via arginine-rich intracellular delivery peptide in plant cellsPlant Cell Physiol.46(3)482-488(2005) 2.Lee, C.-Y., Li, J.-F., Liou, J.-S., et al.A gene delivery system for human cells mediated by both a cell-penetrating peptide and a piggyBac transposaseBiomaterials32(26)6264-6276(2011) 3.Meloni, B.P., Brookes, L.M., Clark, V.W., et al.Poly-arginine and arginine-rich peptides are neuroprotective in stroke modelsJ. Cereb. Blood Flow Metab.35(6)993-1004(2015)
| Cas No. | 143413-47-2 | SDF | |
| 别名 | 九聚精氨酸,Nona-L-arginine; Peptide R9 | ||
| Canonical SMILES | [R][R][R][R][R][R][R][R][R] | ||
| 分子式 | C54H110N36O10 | 分子量 | 1423.69 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.7024 mL | 3.512 mL | 7.024 mL |
| 5 mM | 0.1405 mL | 0.7024 mL | 1.4048 mL |
| 10 mM | 0.0702 mL | 0.3512 mL | 0.7024 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。